Functional Vision in TBI

June 14, 2017 updated by: VA Office of Research and Development

Functional Vision Consequences of Rehabilitation for TBI Vision Loss

The objective of this study is to test functional vision outcome measures that reflect the loss in everyday life tasks that require vision and that are sensitive to changes after a course of vision rehabilitation in Veterans/participants with TBI.

Study Overview

Detailed Description

Traumatic brain injury (TBI) can cause vision loss because of diffuse or focal neuronal injury. Vision can be compromised because of local injury to one or both optic nerves, diffuse brain injury, and/or limitation in eye movements because of dysfunction of cranial nerves. These typical injuries may compromise any of the neural pathways that subserve afferent or efferent visual function. Self-reports of vision loss include diplopia, visual field loss, light sensitivity, reading problems and contrast sensitivity (color and luminance) loss. This project will pursue the following aims: 1) Identify the relationship between functional vision loss in everyday vision tasks (reading, visual search, way finding) and the characteristics of potential visual impairment (visual acuity, contrast sensitivity, visual fields, stereoacuity, eye movement disorders) associated with TBI; and 2) Determine the ability of the vision rehabilitation interventions (both monotherapy and combination therapy) to improve functional vision outcome measures that reflect everyday visual tasks. The vision rehabilitation interventions incorporated into this study will be Vision Restoration Therapy, NVT Eye Scanning Therapy, and standard Eccentric Viewing Training. These therapies are rehabilitative interventions prescribed for Veterans in Polytrauma Rehabilitation Centers, Blind Rehabilitation Centers, and advocated for VA Medical Center TBI clinics.

Study Type

Interventional

Enrollment (Anticipated)

110

Phase

  • Phase 4

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • California
      • Palo Alto, California, United States, 94304-1290
        • VA Palo Alto Health Care System

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 77 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • TBI (any form)
  • Hemianopic Visual Field Loss
  • Stable fixation
  • 1.0 logMAR or better Reading Acuity
  • 20 words per minute or better reading rate

Exclusion Criteria:

  • Visual Neglect
  • medical conditions that prevent sitting for 30 minutes or following instructions

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Crossover Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Active Comparator: Arm 1
Group 1 - Combination Treatment
Therapy that enhances the neuronal plasticity of the visual system
Therapy that trains eye and head scanning into the blind hemianoptic visual field
Active Comparator: Arm 2
Group 2 - Combination Treatment
Therapy that trains the person to compensate for visual field loss by learning to move the visual field loss to the position that is least likely to impact the current visual task
Active Comparator: Arm 3
Group 3 - Combination Treatment
Therapy that enhances the neuronal plasticity of the visual system
Therapy that trains eye and head scanning into the blind hemianoptic visual field
Active Comparator: Arm 4
Group 4 - Combination Treatment
Therapy that trains the person to compensate for visual field loss by learning to move the visual field loss to the position that is least likely to impact the current visual task
Active Comparator: Arm 5
Group 5 - Monotherapy Treatment
Therapy that enhances the neuronal plasticity of the visual system
Therapy that encourages subjects to do daily visual tasks at home while having no training or intended intervention benefit
Active Comparator: Arm 6
Group 6 - Monotherapy Treatment
Therapy that trains the person to compensate for visual field loss by learning to move the visual field loss to the position that is least likely to impact the current visual task
Therapy that encourages subjects to do daily visual tasks at home while having no training or intended intervention benefit
Active Comparator: Arm 7
Group 7 - Monotherapy Treatment
Therapy that trains eye and head scanning into the blind hemianoptic visual field
Therapy that encourages subjects to do daily visual tasks at home while having no training or intended intervention benefit

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Dynamic Visual Field
Time Frame: Baseline
Baseline

Secondary Outcome Measures

Outcome Measure
Time Frame
Dynamic Visual Field
Time Frame: After First Therapy / Before Second Therapy (Average time is 4.5 months)
After First Therapy / Before Second Therapy (Average time is 4.5 months)
Dynamic Visual Field
Time Frame: After Second Therapy (Average Time is 9 months)
After Second Therapy (Average Time is 9 months)
Reading Rate and Accuracy
Time Frame: Baseline
Baseline
Reading Rate
Time Frame: After First Therapy / Before Second Therapy (average time is 4.5 months)
After First Therapy / Before Second Therapy (average time is 4.5 months)
Reading Rate and Accuracy
Time Frame: After Second Therapy (average time is 9 months)
After Second Therapy (average time is 9 months)
Visual Search Accuracy and Timing
Time Frame: Baseline
Baseline
Visual Search Accuracy and Timing
Time Frame: After First Therapy / Before Second Therapy (average time is 4.5 months)
After First Therapy / Before Second Therapy (average time is 4.5 months)
Visual Search Accuracy and Timing
Time Frame: After Second Therapy (average time is 9 months)
After Second Therapy (average time is 9 months)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Ron Schuchard, PhD, VA Palo Alto Health Care System

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 1, 2012

Primary Completion (Actual)

November 21, 2013

Study Completion (Actual)

November 21, 2013

Study Registration Dates

First Submitted

September 14, 2010

First Submitted That Met QC Criteria

September 30, 2010

First Posted (Estimate)

October 4, 2010

Study Record Updates

Last Update Posted (Actual)

June 16, 2017

Last Update Submitted That Met QC Criteria

June 14, 2017

Last Verified

June 1, 2017

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Brain Injuries

Clinical Trials on Vision Restoration Therapy

3
Subscribe